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Abstract
 
Chagas’ disease is a major health and economic problem caused by the protozoan 
 
Trypanosoma
cruzi
 
. Multiple independently evolving clones define a complex parasite population that can be
arranged into two broad genetic lineages termed 
 
T. cruzi
 
 I and II. These lineages have different
evolutionary origin and display distinct ecological and biological traits. Here we describe a
novel molecule termed TSSA for trypomastigote small surface antigen that provides the first
immunological marker allowing discrimination between lineages. TSSA is a surface, glyco-
sylphosphatidyl inositol (GPI)-anchored mucin-like protein, highly antigenic during the infec-
tion. TSSA sequences from different parasite isolates reveal a population dimorphism that per-
fectly matches with the two 
 
T. cruzi
 
 lineages. Interestingly, this dimorphism is restricted to the
central region of the molecule, which comprises the immunodominant B cell epitopes. This
sequence variability has a major impact on TSSA antigenicity, leading to no immunological
cross-reactivity between both isoforms for antibodies present either in immunization or infec-
tion sera. Furthermore, the absolute seroprevalence for TSSA in confirmed Chagasic patients is
restricted to 
 
T. cruzi
 
 II isoform, strongly suggesting that human infections are due to this partic-
ular subgroup. Even though association of 
 
T. cruzi
 
 II with Chagas’ disease has been proposed
based on molecular markers, this is the first immunological evidence supporting this hypothesis.
The implications of these results for the future research on Chagas’ disease could be envisaged.
Key words:
 
Trypanosoma cruzi
 
 • mucin-like • lineage dimorphism • Chagas’ disease • 
serodiagnosis
 
Introduction
 
Trypanosoma cruzi
 
 is the etiological agent of Chagas’ disease,
an endemic illness that affects 18 million people in Latin
America (1). The parasite alternates its life cycle between
vertebrates and insect vectors, with different developmental
stages involved in each host (2). Within the reduviid vector
two forms of the parasite can be observed: replicative epi-
mastigotes and metacyclic trypomastigotes. The latter form
brings the infection into humans when released on the skin
or mucosa with the depositions of the bug. After cell inva-
sion, metacyclic trypomastigotes differentiate into the repli-
cative amastigote form that, after several divisions, differen-
tiates into bloodstream trypomastigotes. The latter stage is
able to invade a wide variety of nucleated cells, thus prop-
agating the infection. The cycle closes when the he-
matophagous vector ingests circulating trypomastigotes
with its blood meal.
After an acute phase characterized by a high parasitemia,
the infection progress to a chronic stage, where parasites are
barely detected. In 35% of the human cases pathological
signs such as myocarditis and neurodegenerative effects on
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the digestive system would appear, thus leading to Chagas’
disease (1). The incidence of acute cases in humans is
steadily declining in a number of countries mainly due to
the successful control of vectorial transmission (1). How-
ever, as 
 
T. cruzi
 
 develops a life-long infection in humans,
these people can serve as parasite reservoirs throughout
their lifetime. Thus, the risk of congenital and/or horizon-
tal transmission by infected blood transfusion may become
a major problem in nonendemic regions, increased by the
migration of people from endemic areas in South and Cen-
tral America to the developed countries (1). In this context,
the identification of new immunodominant parasite mole-
cules reliable for serodiagnosis is desirable (3).
 
T. cruzi
 
 is grossly divided into two divergent genetic
groups or lineages, called 
 
T. cruzi
 
 I and II that include all
typed strains and cloned stocks thus far isolated (4–6), al-
though further subdivisions are possible (7, 8). This popula-
tion structure is a consequence of both its divergent evo-
lutionary history (9) and its clonal rather than sexual
propagation (10). Diversity among parasite isolates has been
early noted, mainly based on biochemical, ecological, and
epidemiological data (11). More recently, several molecular
markers have been identified that allow the conformation of
two broad lineages and a more accurate discrimination be-
tween isolates. These markers include the 24S
 
 
 
rRNA gene
and its promoter sequence (5, 12), the intergenic region of
the tandemly repeated mini-exon gene (5) and microsatel-
lite DNA (13). Current biological and epidemiological data
provide evidence for a strong association of 
 
T. cruzi
 
 II with
human disease whereas 
 
T. cruzi
 
 I is preferentially detected
in the sylvatic cycle (affecting mainly American marsupials
and edentates; references 6 and 14). However, a state-of-
the-art demonstration of this assumption is still lacking.
 
TcMUC 
 
is a complex 
 
T. cruzi
 
 family of genes that resem-
ble vertebrate mucin genes (15, 16), comprising 500 to 700
members per haploid genome (17, 18). Accordingly to the
structure of the deduced proteins three groups of genes
were conformed (17). All of them code for short Thr, Ser,
and Pro-rich proteins that share highly homologous N- and
COOH-terminal regions, encoding for an endoplasmic
reticulum targeting signal and a glycosylphosphatidyl inosi-
tol (GPI)
 
*
 
 anchor attachment signal, respectively (17). Di-
vergences that account for their classification on different
groups arise mainly in their central domains. Mucin mole-
cules belonging to group I were identified on the surface of
the vertebrate stages of 
 
T. cruzi
 
 and have Thr
 
(8)
 
-Lys-Pro
 
(2)
 
tandem repeats in the central region that become highly
 
O
 
-glycosylated in vivo (19). The products of group II dis-
play nonrepeated unique central sequences and their expres-
sion at the protein level have never been confirmed in the
parasite. Nevertheless the deduced products are rich enough
in Thr, Ser, and Pro residues as to support its mucin-like
denomination (17, 20). Finally, group III yielded a very
small-deduced product that displays no significant homolo-
gies with anything in the sequences databases (17).
In the present work, we show that 
 
TcMUC
 
 group III is
actually conformed by a dimorphic single-copy gene, with
two alleles distributed among the parasite isolates coincid-
ing with the two broad lineages postulated for 
 
T. cruzi
 
 (5,
6). The expression of its encoded protein was verified in
the surface of the cell-derived trypomastigotes. Therefore,
we named it trypomastigote small surface antigen (TSSA)
given that the product is highly immunogenic during 
 
T.
cruzi
 
 infections in humans and laboratory animals. By using
peptide scanning we demonstrated that the Ab recognition
was mainly restricted to epitope(s) contained within a sin-
gle 10-amino acid long peptide. Interestingly, sequence
differences observed for the two alleles found in the species
were mainly clustered within this antigenic region and lead
to no immunological cross-reactivity between both iso-
forms. More important, the high prevalence (100% among
confirmed Chagasic individuals and 
 
 
 
87% among poten-
tially Chagasic individuals) of anti-TSSA Abs is exclusively
attributed to 
 
T. cruzi
 
 II isoform. Thus, we propose TSSA as
the first immunological marker of 
 
T. cruzi
 
 genetic sub-
groups that correlates human infection with 
 
T. cruzi
 
 II.
 
Materials and Methods
 
Parasites and Experimental T. cruzi Infection Sera.
 
The CL Bre-
ner genome project reference clone of 
 
T. cruzi
 
 was used for the
antigen characterization (21). The following strains or cloned
stocks were used for DNA preparation and analysis: CL, RA, Y,
Dm28c, Tulahuen2, SilvioX10 (5), AWP, Mg, ITN, UP (22),
CA-I/69, CA-I/72, Miranda (23), Peru (12), Tulahuen0 (24),
GER, #2538, and #2378 (cloned stocks isolated from chronic
Chagasic patients from Brazil (GER) and Argentina (#2538 and
#2378), our unpublished results). Sera from BALB/c mice in-
fected by the intraperitoneal route with a nonlethal dose of 10
 
3
 
CL Brener bloodstream trypomastigotes and bled at different
times postinfection were provided by Dr. S. Leguizamón (Depto.
de Microbiología, Facultad de Medina, Universidad de Buenos
Aires, Buenos Aires, Argentina). Additional sera from BALB/c
infected mice were provided by Dr. M.M. Teixeira (Departa-
mento de Parasitologia, Instituto de Ciências Biomédicas, Uni-
versidade de São Paulo, São Paulo, Brazil). Sera from Wistar rats
infected with 10
 
6
 
 SilvioX10 or Miranda bloodstream trypomas-
tigotes by the intravenous route were provided by Dr. J. Bua (In-
stituto Nacional de Parasitología “Dr. M. Fatala Chaben,” Bue-
nos Aires, Argentina). Further sera from rabbits infected with
different 
 
T. cruzi
 
 isolates were a generous gift from Dr. D.
Sánchez (IIB-INTECH, UNSAM, Buenos Aires, Argentina).
 
Human Sera Survey.
 
Sera were collected from 460 people liv-
ing in different endemic and nonendemic geographic areas in Ar-
gentina (66 potentially Chagasic individuals and 10 non-Chagasic
individuals), Brazil (112 potentially Chagasic individuals, 123
confirmed Chagasic individuals, and 126 non-Chagasic individu-
als) and Chile (23 potentially Chagasic individuals). Some of the
Brazilian confirmed Chagasic patients were coinfected with HIV.
Brazilian human serum samples were provided by Dr. D.T. Co-
vas (Fundação Hemocentro de Ribeirão Preto, Ribeirão Preto,
Brazil), Dr. A. Fragata Filho (Instituto Dante Pazzanese de Cardi-
ologia, São Paulo, Brazil), and Dr. M.A. Shikanai-Yasuda (Insti-
tuto de Medicina Tropical, Universidade de São Paulo, São
Paulo, Brazil). Argentinean serum samples were purchased from
the Instituto Nacional de Parasitología “Dr. M. Fatala Chaben.”
 
*
 
Abbreviations used in this paper:
 
 GPI, glycosylphosphatidyl inositol; TSSA,
trypomastigote small surface antigen. 
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Chilean serum samples were a gift from Dr. J. Gonzales (Unidad
de Parasitologia, Universidad de Antofagasta, Antofagasta, Chile).
All sera were diagnosed by three independent assays (ELISA using
total parasite homogenate, indirect immunohemaglutination
[IHA], and indirect immunofluorescence [IFI]). In addition, some
patients were also tested by chemiluminescent-ELISA (CL-
ELISA, see below) using an epimastigote preparation as antigen
(25) and/or for the presence of 
 
T. cruzi
 
 in the total blood by
hemoculture (26). Individuals were grouped as potentially Cha-
gasic (those rendering positive results only for conventional serol-
ogy) or confirmed Chagasic (those rendering positive results both
for conventional serology and hemoculture).
 
Expression of TSSA as a GST-fusion Protein and Antisera Develop-
ment.
 
A fragment of both 
 
tssa
 
-I (from Dm28c) and 
 
tssa
 
-II (from
CL Brener) genes was amplified by PCR using the oligonu-
cleotides PsMUC/Bam (5
 
 
 
-CGTGGATCCTTGGTGCTCGC-
CCTGTGCT-3
 
 
 
) and DGS/Eco (5
 
 
 
-CGGGAATTCAGCT-
GCCGAGGCTGCCGTC-3
 
 
 
; Fig. 1). The products were
BamHI/EcoRI digested and cloned into pGEX-2T (Amersham
Pharmacia Biotech). Expression and purification of the ensuing
GST-TSSA-I and GST-TSSA-II chimeric proteins were done as
described elsewhere (19). For the production of specific antisera,
100 
 
 
 
g of either GST-TSSA were emulsified in CFA (Sigma-
Aldrich) and injected into rabbits by the subcutaneous route.
Two boosters of 50 
 
 
 
g each in IFA were given at days 30 and 45
postinjection. A similar immunization schedule was followed
with mice (C3H/HeN) but using 25, 5, and 5 
 
 
 
g doses, respec-
tively, by the intraperitoneal route.
 
Purification of TSSA-II–specific Abs from Chagasic Sera.
 
Puri-
fied GST-TSSA-II (1 mg) was immobilized on a NHS-activated
column (HiTrap
 
®
 
; Amersham Pharmacia Biotech) following
manufacturer’s guidelines. Samples (100 
 
 
 
l each) of 10 Chagasic
sera selected on the basis of their high reactivity against GST-
TSSA-II were pooled, diluted to 10 ml in Tris-buffered saline
0.15 M pH 7.6 containing 0.1% Tween 20 (TBS-T), and applied
onto the GST-TSSA-II column. After extensive washing with
TBS, affinity-retained Abs were eluted with 5 ml of glycine 0.1 M
pH 3 and immediately neutralized with a few drops of Tris-HCl,
1 M, pH 8.
 
ELISA.
 
Polystyrene ELISA microplates (Maxisorp; Nunc)
were coated with 100 ng of the indicated antigen in PBS. Blocking
of the plates were made in TBS-T supplemented with 5% nonfat
dried milk. Appropriate dilutions of serum samples in the same so-
lution were incubated for 1 h at room temperature and captured
Abs were evaluated by the addition of secondary Abs coupled to
HRPO (1:10,000 dilution; Dako) followed by 2,2
 
 
 
-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) (Roche Diagnostics). Plates
were read at 405 nm in a microplate reader (Bio-Rad Laborato-
ries). Samples obtained from healthy patients or animals were used
as negative controls. Serum samples giving OD values higher than
the mean obtained for the negative population 
 
 
 
 3 SD were re-
corded as positive. Alternatively, anti-TSSA Abs were evaluated by
the more sensitive CL-ELISA as described previously (25, 27). For
this assay, plates were coated either with 10 or 20 ng of the recom-
binant molecules and sera from Chagasic and non-Chagasic indi-
viduals or 
 
T. cruzi
 
–infected animals tested as indicated.
 
SPOT Assays.
 
Immobilized peptide SPOTs (28) were pro-
cessed as described by the manufacturers (Sigma-Genosys) with
subtle modifications. Briefly, membranes were blocked overnight
in casein based blocking reagent (Sigma-Genosys) supplemented
with 1% nonfat dried milk. Sera were diluted 1:100 in the same
solution and incubated for 3 h. After extensive washings, second-
ary Abs coupled to HRPO were added and reaction developed
 
by chemiluminescence with WestPico SuperSignal substrate
(Pierce Chemical Co.).
 
DNA and RNA Purification and Hybridization.
 
DNA was pre-
pared from 
 
T. cruzi
 
 epimastigotes by proteinase K-phenol/chlo-
roform extraction (15). Parasite RNA was prepared from the dif-
ferent developmental stages (obtained as described in reference
15) using TRIzol
 
®
 
 (Life Technologies) according to manufac-
turer’s guidelines. After nucleic acid immobilization onto
Z-probe membranes (Bio-Rad Laboratories) Southern and
Northern blot assays were performed as described elsewhere (15).
The 
 
tssa
 
-II–specific probe was synthesized by PCR using the oli-
gonucleotides EMT5/s (5
 
 
 
-ACAGCGAATGGTGGGTCT-3
 
 
 
)
and EMT5/a (5
 
 
 
-TTTGAGGAGGCTTCTGCTTC-3
 
 
 
) (Fig.
1). Hybridization was performed in SSC/SDS/Denhardt solution
and washings performed under high stringency conditions (65
 
 
 
C,
0.1
 
 
 
 SSC, 0.1% SDS) as described (15).
 
Cloning of tssa from Different T. cruzi Isolates.
 
The 
 
tssa
 
 alleles
were cloned by PCR using 100 ng of genomic DNA of the
Tulahuen2, Dm28c, Y, RA, CA-I/72, and Silvio
 
 
 
10 isolates as
template. Two reactions were necessary to isolate the complete
genes given that the 
 
TcMUC
 
 family has highly conserved ends
(17). In a first set of reactions the oligonucleotide T5/ATG/E
(5
 
 
 
-CGGAATTCATGACTACGTGCCGTCT-3
 
 
 
) was used in
combination with the oligonucleotide EMT5/a and, in a second
reaction, the oligonucleotide STOP (5
 
 
 
-TCAGCCCAGAGTG-
GTGTACGC-3
 
 
 
) was used in combination with the oligonucle-
otide EMT5/s (Fig. 1). The products were cloned in pGEM
 
®
 
T-Easy (Promega) and fully sequenced using the Sequenase 2.0
kit (United States Biochemical Corp.). The complete sequences
of the deduced proteins shown for each strain in Fig. 4 B are a
mosaic of these two sequences except for CL Brener.
 
tssa, Mini-Exon, and rDNA Gene-typing of T. cruzi Isolates.
 
A
fragment of the 
 
tssa
 
 alleles from several isolates was amplified
from genomic samples using the oligonucleotides T5/ATG/E
and EMT5/a as described above. The amplification product was
treated with PvuII for 3 h and subsequently resolved in a 10%
polyacrylamide/TBE gel followed by ethidium bromide staining.
In addition, aliquots of the same genomic samples were used as
templates for amplification of the intergenic region of the mini-
exon genes and the divergent domain of the 24S
 
 
 
rRNA gene as
described (5).
 
PI-PLC Treatment.
 
Cell-derived trypomastigotes (2 
 
 
 
 10
 
8
 
)
were washed twice in PBS and resuspended in 500 
 
 
 
l of
D-MEM (Life Technologies). Parasites were incubated for 3 h at
37
 
 
 
C with or without the addition of 4 U of phosphatidylinosi-
tol-specific phospholipase C (PI-PLC) from 
 
Bacillus cereus
 
 (Sigma-
Aldrich), washed in PBS, and pellets and concentrated condi-
tioned media aliquots prepared for Western blotting analysis.
 
Parasite Lysates and Western Blotting.
 
PBS-washed parasites
were resuspended to 10
 
6
 
 parasites per 
 
 
 
l in TBS 1% Triton X-100
with 1 mM PMSF, 0.5 mM 
 
N
 
   
 
p-tosyl-
 
l
 
-lysine chloromethyl
ketone, and 100 
 
 
 
g/ml DNase (all from Sigma-Aldrich). SDS was
added to 1% and lysates boiled for 5 min. Total lysates corre-
sponding to 2 
 
 
 
 10
 
7
 
 parasites of each stage were separated by
SDS-PAGE and transferred to nitrocellulose membranes (Amer-
sham Pharmacia Biotech; reference 29). Filters were probed with
an anti GST-TSSA-II serum and revealed using HRPO-conju-
gated secondary Abs followed by chemiluminescence detection.
 
Indirect Immunofluorescence.
 
A drop of parasites resuspended at
5 
 
 
 
 10
 
6
 
 per ml in PBS was layered onto a 3-aminopropyltri-
ethoxysilane (Sigma-Aldrich) coated round coverslips and let
stand for 30 min at room temperature. Parasites were fixed with
the nonpermeabilizing reagent 4% paraformaldehyde (29) for 30 
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min. Blocking (1 h incubation) and Ab dilutions were in PBS
containing 2% BSA and 5% normal rabbit serum. Blocking buffer
was supplemented with 25 mM NH
 
4
 
Cl. Anti GST-TSSA-II
mouse serum diluted 1:100 was allowed to react for 1 h followed
by washing in PBS 2% BSA. FITC-conjugated anti-mouse IgG
(Fab
 
 
 
)
 
2 
 
raised in rabbit (Dako) were added for additional 60 min
and washed as above. Coverslips were mounted in 50% glycerol
in PBS and observed and photographed using an Olympus IX50
inverted fluorescence microscope.
 
Results
 
Description of a TSSA Belonging to the TcMUC Family.
 
As a first step toward the characterization of the group III
of 
 
TcMUC
 
 gene-family, three cDNA clones obtained from
the CL Brener clone (17) were completely sequenced.
Two further sequences from CL Brener were downloaded
from GenBank: EST TENU3264 and GSSTc10735
(GenBank/EMBL/DDBJ accession nos. AI077116 and
AZ049892, respectively). They all seemed to be derived
from the same gene given that no nucleotide differences
were detected among them. The open reading frame
spanned 276 bp rendering a 92-amino acid long deduced
product (Fig. 1). Comparison of this product with those
from TcMUC groups I and II showed a predicted 26-
amino acid long signal peptide at the NH
 
2
 
 terminus (30),
73% identical to the consensus of the family (17). Likewise,
the last 27 amino acid residues were compatible with a
GPI-anchoring signal with 85% identity to the one de-
scribed for groups I and II (17). As these two regions were
shown to be functional for 
 
TcMUC
 
 genes in 
 
T. cruzi
 
 (19)
the mature product could be predicted with some confi-
dence. Therefore, this protein would be 40-amino acid
long after these two regions were intracellularly processed,
with a 
 
M
 
r
 
 of 3,747 D and a pI of 4.13. The mature protein
 
has a high content of hydroxyamino acids (32.5% Ser 
 
 
 
Thr), Pro (12.5%), Gly (15%), and Ala (12.5%) residues.
This biased amino acid composition, along with the exist-
ence of 10 putative 
 
O
 
-glycosylation sites (31; Fig. 1), sug-
gests that this gene encode for a 
 
T. cruzi
 
 mucin-like mole-
cule. As will be shown below, this is a surface antigen
expressed in the trypomastigote stage and was so named
TSSA after trypomastigote small surface antigen.
 
Genomic Organization and Gene Expression of tssa.
 
The
genomic organization of 
 
tssa
 
 was analyzed by Southern blot
using a probe that encompassed the central region of the
CL Brener 
 
tssa
 
 gene. This probe did not cross-hybridize
with genes from groups I and II of the 
 
TcMUC
 
 family as it
excludes any conserved region (17). The hybridization pat-
tern was compatible with the existence of a single gene per
haploid genome (Fig. 2 A). In addition to the Southern
blot, two further evidences reinforced the previous state-
ment. First, a search in a 
 
T. cruzi
 
 genomic sequence survey
database (18) using the 
 
tssa
 
 central region as query rendered
only one hit (GSSTc10735). Second, hybridization of a 
 
T.
cruzi
 
 CL Brener cosmid library ordered in a high-density
array (32) with the same probe produced 0.8 positive sig-
nals when normalized per haploid genome (17). Alto-
gether, these results strongly suggest that 
 
tssa
 
 is a single-
copy gene at least in the CL Brener clone.
The same probe was used in a Northern blot assay re-
vealing that the 
 
tssa
 
 mRNA is present in all the develop-
mental stages of the parasite (Fig. 2 B). The steady-state
levels of 
 
tssa
 
 mRNA varied among the stages being more
abundant in metacyclic trypomastigotes. This expression
pattern contrasted with that observed for the TSSA pro-
tein, which is mostly expressed in cell-derived trypomasti-
gotes (Fig. 3, A and B). It should be noted, however, that
posttranscriptional regulation is the rule in 
 
T. cruzi
 
 gene
expression (33, 34) and some examples have been described
in which protein abundance did not correlate with steady-
state mRNA levels (35). As this seems to be the case for
 
tssa
 
, the 3
 
 
 
 untranslated region (UTR) of its transcript was
analyzed for possible posttranscriptional regulatory ele-
ments placed in cis. The scheme presented in Fig. 2 C
shows the presence of AU-rich elements found in the 
 
tssa
 
3
 
 
 
 UTR that were already shown to regulate the stability of
mucin-gene transcripts in 
 
T. cruzi
 
 (36, 37). Although only
structural, the antecedents in the field allow the presump-
tion that posttranscriptional regulation plays an important
role in the expression of the 
 
tssa
 
 gene.
 
Detection and Characterization of the TSSA Product.
 
A
fragment of the coding region of the 
 
tssa
 
 allele obtained
from the CL Brener clone (Fig. 1) was expressed as a GST
fusion and used to raise specific antisera in rabbits and mice.
Both kinds of antisera were tested against total parasite ly-
sates by Western blotting and reacted against a single 20-
kD band present in cell-derived trypomastigote lysates (Fig.
3 A, and data not shown). Due to the discrepancy between
the predicted and observed 
 
M
 
r
 
, anti-GST-TSSA Abs were
affinity-purified from a pool of TSSA-reactive Chagasic
sera and used to probe 
 
T. cruzi
 
 lysates to ascertain the spec-
ificity of the signal. These Abs recognized the same 20-kD
Figure 1. Primary structure and features of the TSSA. The deduced
amino acid sequence of TSSA obtained from the CL Brener gene is indi-
cated. Ser and Thr residues predicted to be O-glycosylated are shaded.
The predicted signal peptide cleavage site (open triangle) and the putative
GPI anchor addition (vertical arrow) are indicated. Sequence between
asterisks indicates the fragment expressed as GST-fusion. The position
and names of the oligonucleotides used in this work are indicated above
the corresponding spanned protein sequence. 
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protein in cell-derived trypomastigote lysates although a
faint signal was observed also in amastigotes and metacyclic
trypomastigotes (Fig. 3 B).
As the deduced protein had a putative GPI anchor signal
(Fig. 1), the presence of such modification in TSSA was
evaluated by PI-PLC treatment on intact cell-derived try-
pomastigotes. The addition of PI-PLC caused the disap-
pearance of the signal in lysates from treated parasites when
probed with an anti-GST-TSSA serum in Western blotting
(Fig. 3 C). Nevertheless, the band was not recovered in the
culture supernatant. As a control, the same filter was probed
with an antiserum raised against shed acute-phase antigen
(SAPA), a cell-derived trypomastigote surface antigen
known to be GPI-anchored and readily shed into the me-
dium by the same PI-PLC treatment (38). SAPA was solu-
bilized and detected in its intact form in the supernatant af-
ter the treatment (Fig. 3 C). So, it seems that the failure to
detect soluble TSSA in the filter was due to the inability of
the released protein to bind to nitrocellulose membranes.
The surface localization of TSSA was further assessed by
indirect immunofluorescence on nonpermeabilized para-
sites. The surface of cell-derived trypomastigotes was
clearly labeled by anti-TSSA Abs but not by a mouse nor-
mal serum (Fig. 3, D and E). Broad trypomastigote forms
were more strongly labeled than slender trypomastigotes.
On the other hand, amastigotes were only faintly labeled
Figure 2. Genomic organization and expression of tssa. (A) Southern
blot of genomic DNA from T. cruzi CL Brener (1  g/lane) digested using
the indicated enzymes, transferred to membranes, and hybridized under
stringent conditions with the tssa probe. Size markers (in kpb) are indicated
on the left. (B) Northern blot of total T. cruzi CL Brener RNA purified
from metacyclic trypomastigotes (M), epimastigotes (E), cell-derived trypo-
mastigotes (T), and amastigotes (A) using the tssa probe under stringent
conditions. The position of the rRNA components are shown on the left as
size indication (reference 46). Control for assessing similar lane loading was
performed by using the 24S rRNA probe. (C) In scale scheme of the ge-
nomic CL Brener tssa locus (above) and its derived mature mRNA as de-
duced from DNA and cDNA sequencing and restriction mapping. The
recognition sites for restriction enzymes used in the Southern blotting are
indicated. AG, splice leader acceptor site; pA, polyadenylation acceptor site.
Figure 3. Stage-specific expression of TSSA. (A and B) Western blot of
total lysates from T. cruzi (CL Brener clone) metacyclic trypomastigotes
(M), epimastigotes (E), cell-derived trypomastigotes (T), and amastigotes
(A). Approximately 2   107 parasites were loaded in each lane of a SDS-
PAGE gel and assayed by Western blotting with an anti-GST-TSSA se-
rum raised in mouse (A) or with a pool of anti-TSSA affinity-purified Abs
from Chagasic sera (B). In both panels Mr markers (in kD) are indicated on
the left. (C) Intact live cell–derived trypomastigotes were treated ( ) or
not ( ) with B. cereus PI-PLC. Normal morphology and motility was
controlled by microscopic observation before and after the incubation
time. Parasites were lysed and aliquots from total lysates and supernatants
(sn) were sequentially probed with an anti–GST-TSSA serum raised in
mouse and an anti-GST-SAPA serum raised in rabbit by Western blotting.
Ponceau staining of the membrane is shown to assess similar lane loading.
nt, nontreated parasites. (D and E) A mixture of cell-derived trypomas-
tigotes, amastigotes, and intermediate forms were analyzed by indirect
immunofluorescence. Parasites were probed using normal mouse serum
(D), or an anti-GST-TSSA serum raised in mouse (E) and photographed
(180  magnification) under phase contrast and fluorescence. 
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(Fig. 3 E). Axenic culture-derived insect parasite stages
(epimastigotes and metacyclic trypomastigotes) gave no re-
action by this technique (data not shown). Along with re-
sults obtained from the Western blotting it is concluded
that TSSA is a surface antigen mainly expressed in the cell-
derived trypomastigote stage.
 
Interstrain Variability of TSSA.
 
The analysis of several 
 
T.
cruzi
 
 isolates by Southern blotting with the 
 
tssa
 
 probe indi-
cated that the genomic organization and gene copy number
was conserved among isolates. However, differences in the
signal intensity were noted when comparing the isolates,
which might denote certain degree of heterogeneity within
Figure 4. Inter-strain variability of TSSA. (A) Genomic DNA from the indicated T. cruzi strains or cloned stocks was digested by ApaLI and hybridized
under stringent conditions with the tssa probe. Size markers (in kpb) are indicated on the left. (B) Comparison of the deduced TSSA amino acid sequences
from the indicated parasite isolates. Isolates were classified as T. cruzi I or II according to reference 5. Amino acid identities with the CL Brener sequence
are shadowed. Hyphens were introduced for better alignment. (C) tssa and lineage typing of T. cruzi strains and cloned stocks. A fragment of the tssa gene
was amplified from DNA samples of the indicated isolates, digested with PvuII and resolved by PAGE. From the same samples the rDNA and mini-exon
intron were amplified and resolved in agarose gels. An example of the pattern observed for each lineage as determined in this work for tssa and already de-
scribed for the rDNA and mini-exon (reference 5) is shown at left. The results for all the isolates are summarized in the table at right. ND, not determined. 
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this locus (Fig. 4 A). To clarify this issue, 
 
tssa
 
 alleles were
cloned and sequenced from Y and RA strains (both ren-
dering strong signals on the Southern blot) and Dm28c
and Tulahuen2 isolates (that rendered weak signals on the
Southern blot; Fig. 4 A). The 
 
tssa
 
 gene from SilvioX10
and CA-I/72, not assayed in the Southern blot, were also
cloned and sequenced. The resulting deduced proteins
showed that two forms of 
 
tssa
 
 existed within the species
yielding two different kinds of TSSA proteins (Fig. 4 B).
Even though minor changes were observed in the NH
 
2
 
-
terminal peptide and the putative GPI anchor, the inter-
strain variability was mainly focused to the central region.
Interestingly, this dimorphism seemed to correlate with
the two major evolutive lineages proposed for 
 
T. cruzi
 
 (5,
6; Fig. 4 B). To further evaluate this possibility 
 
tssa
 
 alleles
from several 
 
T. cruzi
 
 strains or cloned stocks were typed
by endonuclease restriction after PCR amplification of
their central regions. A unique PvuII site exclusively
present in the variable region of the 
 
tssa
 
 allele from 
 
T.
cruzi
 
 I isolates was used as diagnostic (Fig. 4 C). In addi-
tion, aliquots of the same DNA samples from the different
isolates were typed as 
 
T. cruzi
 
 I or II by analyzing the
PCR product length from the intergenic region of the
tandemly repeated mini-exon gene and the variable re-
gion of the 24S
 
 
 
rRNA gene as originally described (5).
As shown in Fig. 4 C, the 
 
tssa
 
 dimorphism perfectly cor-
related with the existence of these two lineages. Hence,
the 
 
tssa
 
 forms were now called
 
 tssa
 
-I and -II and their en-
coded proteins TSSA-I and TSSA-II as being present in
 
T. cruzi
 
 I and II, respectively.
Ab Recognition of TSSA by Chagasic Patients and Experi-
mentally Infected Animals. The antigenicity of TSSA dur-
ing the infection was first assessed using Chagasic patients’
serum samples obtained from different countries. In a first
series of assays only GST-TSSA-II was used to search for
specific Abs. Each group of samples was heterogeneous,
and included people living in endemic and nonendemic ar-
eas, most probably parasitized by different T. cruzi strains
and showing diverse Chagas’ disease-associated pathology.
The prevalence for TSSA-II specific Abs among Argen-
tinean potentially Chagasic sera was 95.4% (63 out of 66
sera tested) as judged by ELISA (Table I). The overall
TSSA-II reactivity among Brazilian Chagasic sera was
 92% (215 out of 235 sera) and 100% when only hemo-
culturepositive samples (n   123) were considered (Table
I), thus in the range of other immunodominant molecules
currently tested for Chagas’ disease serodiagnosis (3, 39).
Values from Chilean serum samples (87% positive) were in
the same line. None of the 126 normal serum samples as-
sayed were reactive for TSSA-II (Table I).
The antigenicity of TSSA was also evaluated by search-
ing for specific Abs in sera from laboratory animals experi-
mentally infected with different T. cruzi isolates. Most of
the sera tested from T. cruzi II-infected animals (7 out of 7
rabbits, 22 out of 24 mice, and 2 out of 2 rats) were highly
reactive to GST-TSSA-II indicating a marked antigenicity.
Table I. Seroprevalence of Anti–TSSA-I and Anti–TSSA-II Abs in Populations from Distinct Geographical Origins
Percentage of reactive sera
Origin Serum panel n
Conventional serology
(IHA, IFI, ELISA)
reactivity (%)
EpEx CL-ELISAa
reactivity (%) Hemoculture Anti–TSSA-Ib Anti–TSSA-II
Argentina Chagasic 66 100 ND ND 3.0 95.4
Non-Chagasic 10 0 ND ND 0 0
Brazil Chagasicc 112 100 98.2 ND 5.4 82.1
Chagasicd 48 100 100   0 100
Chagasice 75 100 100   2.7 100
Non-Chagasic 126 0 0 ND 0 0
Chile Chagasicc 23 NDf 100 ND 8.7 87.0
Sera were grouped according to the country of origin and diagnosis criteria and tested at 1:200 dilution for TSSA-I and TSSA-II reactivity by ELISA
(Argentinean samples) and/or CL-ELISA (Brazilian and Chilean samples).
aEpEx CL-ELISA, chemiluminescent ELISA test using an epimastigote (Tulahuén strain) preparation as antigen (reference 25).
bPositive sera showed very low reactivity against TSSA-I, with reading (absorbance or relative luminescent unit) values close to the cutoff value for
the specific test. Sera reactive for TSSA-I were also positive for TSSA-II, with reading values for the latter higher than those observed for the former
(see also Fig. 6 C).
cPotentially Chagasic patients.
dConfirmed Chagasic patients.
eConfirmed Chagasic patients coinfected with HIV.
fND, not determined.408 A Marker for the Human-infecting Strains of Trypanosoma cruzi
However, a startling observation was that none of the ani-
mals infected with T. cruzi I isolates reacted against GST-
TSSA-II (addressed more in detail below). To assess the
persistence of anti–TSSA-II Abs during the course of the
infection, a follow up study was performed in BALB/c
mice experimentally infected with the CL Brener clone.
All of them (n   12) showed a peak of TSSA-II–specific
Abs that coincided with the moment of parasitemia declin-
ing and, thereafter, circulating Abs could be detected up to
4 mo postinfection at a fairly constant level (about half of
the peak value, data not shown). The lineage dependence
recognition observed for animal experimental infections
along with the striking high prevalence of anti–TSSA-II
Abs in human infections (Table I) prompted us to study in
more detail the antigenicity of and the immune response
against both TSSA isoforms.
Mapping of Linear B Cell Restricted Epitopes in TSSA-II.
Linear B cell epitopes present in TSSA-II were analyzed by
the SPOT method (28). Overlapping sequences with two-
or five-amino acid residue offset were synthesized onto
membranes in a defined array with 15 peptides covering al-
most the whole TSSA-II deduced protein. These filters
were sequentially tested with two independent Chagasic
sera and a pool of 10 Chagasic sera, rendering almost identi-
cal results (Fig. 5). It was observed that the central region of
TSSA-II contained all the linear antigenic determinants de-
tected by Chagasic sera, whereas the proposed signal pep-
tides and both N- and COOH-terminal portions of the
mature protein gave no reaction. Normal human sera tested
by the same technique rendered negative results (Fig. 5).
Within the central region, every Chagasic sera high-
lighted a major epitope spanning the sequence of peptide
10 (40-KPATGEAPSQ-49; Fig. 5). Interestingly, the anti–
TSSA-II Ab response displayed by T. cruzi II–infected mice
and rabbits was also mainly driven to the same sequence
(Fig. 5), suggesting that the immunodominance of the
epitope(s) included within this peptide is not a species-spe-
cific phenomenon. Another minor epitope, restricted to
humans, might be ascribed to peptide 8 (29-TSSTPPS-
GTEN-39). However, peptide 9 (35-SGTENKPATG-44)
encompassing the proximal and distal half of these two se-
quences, respectively, displayed only a weak signal in two
out of three assays (Fig. 5).
Epidemiological Analysis of TSSA. One striking feature
concerning TSSA is the strain dimorphism depicted in
Fig. 4 B. Variability was restricted to the central region of
the molecule, and involved the two major antigenic pep-
tides (#10 and #8) defined above (Fig. 5). Amino acid se-
quence variation included one single residue deletion and
several nonconservative replacements (in particular the
exchange of 42Pro for Thr) that might have a major impact
on the antigenic structure of TSSA. To evaluate this possi-
bility, we first analyzed the antigenic cross-reactivity be-
tween recombinant TSSA isoforms. For this purpose, we
expressed the central (antigenic) portion of TSSA-I from
Dm28c cloned stock (typed as T. cruzi I, Fig. 4 C; and ref-
erence 5) as GST fusion as already done for TSSA-II (Fig.
1). Both recombinant molecules were probed by ELISA
with different anti-TSSA sera obtained from hyperim-
mune rabbits and mice. As summarized in Fig. 6 A, anti–
TSSA-I sera did not recognize the TSSA-II molecule
even at 1:100 dilution. The reciprocal experiment con-
firmed this, as anti–TSSA-II sera did not recognize TSSA-I
either, suggesting that both molecules display no major
immunological cross-reactivity.
We extended this analysis to the actual infection by
probing sera from animals experimentally infected with
parasite isolates belonging to T. cruzi I or II. As noticed be-
fore, a vast majority of the sera (31 out of 33) from animals
infected with T. cruzi II isolates clearly recognized TSSA-
II, irrespectively of the species analyzed (Table II and Fig.
6 B). On the other hand, recognition of the TSSA-I mole-
cule showed some species dependence for animals infected
with T. cruzi I isolates (Table II and Fig. 6 B). While just 3
out of 12 rabbits detected TSSA-II, 3 out of 5 mice and 5
out of 8 rats were clearly reactive at 1:20 dilution. Not-
Figure 5. Mapping of linear epitopes from TSSA. Peptides were cus-
tom-synthesized by the SPOT technique in a defined array. The region
spanned by each peptide, along with its identification number and posi-
tion in the microarray is indicated. Filters were probed with normal hu-
man (a) or Chagasic sera (b and c). A pool of 10 Chagasic sera (d) was also
used. The same filter was probed with serum pools of eight CL Brener-
infected mice and six RA-infected rabbits.409 Di Noia et al.
withstanding this, lack of immunological cross-reaction
was still the case as the majority of the animals reacted only
to the specific TSSA form present in the lineage they were
infected with (Table II). Only one of the RA (T. cruzi II)-
infected rabbits cross-recognized the TSSA-I protein,
though this reaction was considerably weaker than that
displayed against the TSSA-II molecule (Fig. 6 B). Thus, as
previously demonstrated for the animals immunized with
the recombinant molecules (Fig. 6 A), the in vivo Ab re-
sponse against the TSSA protein core also displayed a
marked specificity.
Interestingly, Chagasic sera showed a similar Ab specific-
ity when tested against both TSSA isoforms at variable se-
rial dilutions as indicated (Table I and Fig. 6 C). The
seroprevalence of anti-TSSA-II Abs among potentially
Chagasic patients was estimated in 87% (175 out 201),
whereas only 5% (10 out of 201) of these sera displayed a
mixed recognition. Among confirmed Chagasic patients
(n     123), seroprevalence of anti–TSSA-II was 100%,
whereas only 2% (2 out of 123) of these sera displayed a
mixed recognition (Table I). All of the latter samples ren-
dered a much stronger reaction with TSSA-II than with
TSSA-I (Fig. 6 C). On the other hand, the few potentially
Chagasic sera that did not recognize TSSA-II neither re-
acted against TSSA-I (data not shown). Altogether, these
results indicate that: (a) every human infection with T.
cruzi involves at least one strain belonging to T. cruzi II;
and (b) none of the Chagasic patients analyzed throughout
this work showed an exclusive T. cruzi I infection, though
a minor proportion of T. cruzi I/T. cruzi II coinfections
could exist.
Discussion
TcMUC is a complex T. cruzi gene-family whose diver-
sity is still not well understood (16, 17). In the present
work we have identified and characterized the product of
TcMUC group III as a small membrane antigen expressed
by the infective cell-derived trypomastigote (Fig. 3, A and
B). This protein, termed TSSA, is encoded by a single-
copy gene (Fig. 2 A) that is dimorphic among T. cruzi iso-
lates correlating with the two broad lineages previously de-
scribed for the species (5, 6; Fig. 4, B and C). A preliminary
biochemical characterization of TSSA was done on the CL
Brener protein since it has been chosen as the genome
project reference clone and the description of its gene
products would be of great interest in the postgenomic
phase (18, 21).
On its COOH terminus, TSSA displayed a hydrophobic
region compatible with a GPI-anchoring signal (17). Fur-
thermore, this sequence is 85% identical to the previously
described in MUC-R (a tagged version of a TcMUC gene),
which rendered a GPI-anchored mucin when transfected
into T. cruzi (19). Amino acid conservation included the
critical tripeptide Asp-Gly-Ser, postulated to function as
the  ,    1, and    2 positions for lipid attachment in
GPI-anchored proteins from T. cruzi and Trypanosoma bru-
cei (40, 41). Two further evidences suggest that TSSA is
GPI-anchored to the parasite surface. First, immunofluo-
rescence of nonpermeabilized parasites clearly labeled the
surface of cell-derived trypomastigotes, specially the broad
forms (Fig. 3 E). Slender trypomastigotes and amastigotes
were faintly labeled (Fig. 3 E) while the insect-derived
stages were negative (data not shown). Broad trypomasti-
gotes might correspond to intermediate forms (2), suggest-
ing that the expression of TSSA is narrowed to defined
periods of the trypomastigote development. Second,
treatment of intact cell-derived trypomastigotes with PI-
PLC resulted in the lost of the signal on parasite lysates
when probed with an anti-TSSA serum in Western blot
(Fig. 3 C). Unexpectedly, this signal was not recovered in
the culture media. The possibility of generalized pro-
teolytic degradation during PI-PLC treatment is unlikely
since another GPI-anchored molecule (SAPA) was recov-
Table II. Seroprevalence of Anti–TSSA-I and Anti–TSSA-II Abs in Infected Animals
Species Infecting T. cruzi isolate T. cruzi group n Anti–TSSA-I positive Anti–TSSA-II positive
Rabbit CA-I, CA-I/72, Tulahuen, AWP I 12 3 0
RA, UP II 7 1b 7
Mouse Laura, Geora, FMSa, Joséa, SEa I5 3 0
CL Brener, RA, Piam 16a, BSIMTa II 24 0 22
Rat SilvioX10 I 8 5 0
Miranda II 2 0 2
Sera were grouped according to the species and infecting T. cruzi strain (T. cruzi I or II) and tested at serial dilution for TSSA-I and TSSA-II reactivity
by CL-ELISA using 20 ng/well of GST-TSSA-I or GST-TSSA-II as coating antigen.
aSerum samples kindly provided by Dr. M.M Teixeira whose infecting strains were gene-typed as T. cruzi I and II using the 24SarRNA and the
mini-exon gene (reference 5).
bReactivity displayed by this serum against TSSA-I was significantly lower than that observed against TSSA-II (see also Fig. 6 B).410 A Marker for the Human-infecting Strains of Trypanosoma cruzi
ered in its intact form in the supernatant (Fig. 3 C). It has
been recently demonstrated that certain GPI-anchored
proteins present in protozoan and mammalian cells suffer a
drastic effect on their antigenicity after the removal of the
GPI lipid moieties, suggesting that they might undergo
conformational changes (42). Whether this phenomenon
might be operating in our system is uncertain but it is
noteworthy the presence of strong linear epitopes on
TSSA (Fig. 5) whose recognition should not, in principle,
be affected by protein conformation. One more likely ex-
planation is that TSSA might be posttranslationally modi-
fied in vivo, in particular by the addition of O-linked oli-
gosaccharides as suggested by its primary sequence (31; Fig.
1). Therefore, the cleavage of its lipid moieties would yield
a highly hydrophilic, soluble TSSA that no longer binds to
nitrocellulose filters, as previously observed for the T. cruzi
trypomastigote total mucins (43, 44). The same explana-
tion could also account for the observed discrepancies be-
tween the predicted and the observed SDS-PAGE mobility
(Fig. 3, A and B). Altogether, these results are compatible
with TSSA being GPI-anchored to the surface of the cell-
derived trypomastigote stage.
Genomic analyses of the tssa locus revealed the existence
of two alleles that code for two distinct forms of the protein
(Fig. 4 B). Interestingly, the distribution of these alleles
correlated with the two major lineages proposed for the
species (5, 6). As shown in Fig. 4 C, lineage classification of
19 T. cruzi isolates by our tssa gene-typing assay showed a
perfect correlation with two of the most commonly used
methods: mini-exon and rDNA PCR polymorphism (5).
Accordingly, it can be proposed that the tssa-I allele is re-
stricted to T. cruzi I isolates (and encodes the TSSA-I iso-
form) and tssa-II is restricted to T. cruzi II isolates (and en-
codes the TSSA-II protein).
In addition to its potential use as a reliable serodiagnostic
molecule (Table I) and a genetic tool for T. cruzi typifica-
tion, TSSA provides with the first immunological marker
allowing the lineage identification of infecting isolates on
serum samples. Amino acid variations between TSSA-I and
TSSA-II are mainly restricted to their central regions (Fig.
4 B), which turned out to comprise the major B cell anti-
genic determinants (Fig. 5). These sequence changes have a
major impact on TSSA antigenicity, leading to negligible
cross-reactivity between both isoforms. As such, anti–
TSSA-I hyperimmune sera did not recognize recombinant
TSSA-II and viceversa (Fig. 6 A). Counterpart in vivo evi-
dence was provided by sera from experimentally infected
animals (Table II and Fig. 6 B) and from Chagasic patients
(Fig. 6 C). Sera from animals infected with T. cruzi II iso-
lates showed an exclusive recognition toward the TSSA-II
molecule. In the same line, although weak anti–TSSA-I
specific responses are elicited during the infection with T.
cruzi I parasites, a proportion of these animals (3 out of 12
rabbits, 3 out of 5 mice, and 5 out of 8 rats) did elicit signif-
icant anti–TSSA-I Abs that were unable to cross-recognize
TSSA-II (Table II and Fig. 6 B). The decreased amounts of
Abs detectable with the TSSA-I recombinant molecule can
be attributed to differences in the course of infection
Figure 6. Analysis of antigenic cross-reactivity between TSSA isoforms.
(A) Reactivity of mouse (diamonds) and rabbit (squares) sera immunized
with the indicated protein against GST (gray symbols), GST-TSSA-I
(black symbols), and GST-TSSA-II (white symbols) recombinant pro-
teins. Each serum was tested in triplicate and mean OD405nm values are
plotted (SD values did not exceed 10% of mean values in any case; not
shown) against reciprocal serum dilution. One out of two experiments
with similar results is shown. The accurate loading of ELISA plates was
verified with an anti-GST polyclonal Ab (data not shown). (B and C)
CL-ELISA assays showing representative examples of the reactivity dis-
played by sera from experimentally-infected animals (B) and Chagasic in-
dividuals (C) against both GST-TSSA-I and GST-TSSA-II recombinant
proteins. NS, normal serum. Parasite isolate used to infect each animal is
indicated below. In the RA/Y lane, the two upper samples were obtained
from RA-infected animals while the two lower samples from Y-infected
animals. Asterisk (*) exemplifies one Chagasic serum showing mixed anti–
TSSA-I/anti–TSSA-II antibody recognition.411 Di Noia et al.
caused by both kinds of parasite lineages. It has been estab-
lished that T. cruzi I isolates develop a mild infection in lab-
oratory animals, characterized by low parasitemia and low
morbidity rate, thus leading to decreased overall reactivity
against parasite antigens (6). Alternatively, it may be pro-
posed that TSSA-I is less immunogenic than TSSA-II or
undergoes major posttranslational modifications in vivo
leading to a decreased Ab response against the TSSA-I pro-
tein backbone. We do not favor the latter hypothesis be-
cause the similarities between the primary sequences of
both proteins (Fig. 4 B) are strong enough to assume that
posttranslational modifications would be similar in kind and
extension. Further biochemical characterization of both
TSSA isoforms should help to clarify this issue.
The major finding of the present work was that, even
though anti–TSSA-I Abs can be readily detected in T. cruzi
I experimental infections (Table II), the seroreactivity dis-
played by Chagasic patients was clearly shifted toward the
recognition of TSSA-II (Table I and Fig. 6 C). As shown,
175 out of 201 (87%) of potentially Chagasic sera and 100%
of confirmed Chagasic sera (n   123) showed specific reac-
tivity against TSSA-II, whereas only 12 out of 324 (3.7%)
total Chagasic serum samples displayed a mixed recognition
(Table I). All of the latter sera, that might have been under-
estimated due to the low titers of Ab directed toward
TSSA-I peptide epitopes elicited during T. cruzi I infec-
tions (Table II), exhibited a much stronger anti–TSSA-II
Ab response (Fig. 6 C). Therefore, they can represent de-
tection of minor cross-reactivities due to Ab populations
directed against common epitopes in both TSSA isoforms,
mostly in high responsive patients. More likely, they can be
interpreted as genuine T. cruzi I/T. cruzi II coinfection
cases (45). It is worth noting that none of the Chagasic sera
analyzed so far showed a restricted recognition toward
TSSA-I. These simple results have a great epidemiological
value as it indicates that strains belonging to T. cruzi II (or
even a subgroup of this lineage) are by far the more com-
mon in producing human infections and, hence, Chagas’
disease. On the other hand, they strongly argue against hu-
man infection cases exclusively due to T. cruzi I strains. Al-
though molecular markers and biological evidences existed
associating T. cruzi II with the domestic cycle of the infec-
tion and T. cruzi I with the sylvatic cycle (6, 14), TSSA
provides with the first antigenic marker supporting this hy-
pothesis. This fact should be kept in mind for reevaluating
previous data obtained in animals experimentally infected
with T. cruzi I isolates and, more important, for choosing
the appropriate strains to develop animal models to study
human pathogenesis and treatments.
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